<--GAT-->

New SGLT2 Inhibitor Approved to Treat Type 2 Diabetes

by U.S. Medicine

February 5, 2014

WASHINGTON A new sodium-glucose co-transporter 2 (SGLT2) inhibitor has been approved to treat type 2 diabetes.

The Food and Drug Administration approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults. Farxiga is marketed by Bristol-Myers Squibb Company, Princeton, NJ, and AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and Farxiga provides an additional treatment option for millions of Americans with type 2 diabetes,” said Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research.

SGLT2 inhibitors block the reabsorption of glucose by the kidney, increase glucose excretion and lower blood glucose levels.

Farxiga’s safety and effectiveness were evaluated in 16 clinical trials involving more than 9,400 patients with type 2 diabetes. The drug was shown to improve patients HbA1c measurements.

The studies involved Farxiga both as a monotherapy and in combination with other type 2 diabetes medications, including metformin, pioglitazone, glimepiride, sitagliptin and insulin.

The FDA noted that Farxiga should not be used to treat people with type 1 diabetes, diabetic ketoacidosis or moderate or severe renal impairment, end stage renal disease or who are on dialysis.

Because an increased number of bladder cancers were diagnosed among Farxiga users in clinical trials, the FDA also does not recommend Farxiga is not recommended for patients with active bladder cancer and suggests that patients with a history of bladder cancer talk to their physician before initiation of the therapy.

Farxiga can cause dehydration, leading to hypotension that can result in dizziness and/or fainting and a decline in renal function. The elderly, patients with impaired renal function and patients on diuretics to treat other conditions appeared to be more susceptible to this risk, the FDA said.

Six post-marketing studies are being required for Farxiga.

Genital mycotic (fungal) infections and urinary tract infections are among the drug’s side effects.


Comments are closed here.


Related Articles

Melanomas Associated With Internal Malignancy Risk

Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.

Some RCC Risk Factors Can Be Modified

Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.


U.S. Medicine Recommends


More From oncology

Oncology

Melanomas Associated With Internal Malignancy Risk

Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.

Oncology

Some RCC Risk Factors Can Be Modified

Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.

Oncology

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Oncology

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up